HSBC Upgrades Moderna to Hold, Lowers Price Target to $69
Portfolio Pulse from Benzinga Newsdesk
HSBC analyst Yifeng Liu has upgraded Moderna (NASDAQ:MRNA) from Reduce to Hold and lowered the price target from $89 to $69.
November 03, 2023 | 9:38 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Moderna's stock rating has been upgraded from Reduce to Hold by HSBC, but the price target has been lowered from $89 to $69.
The upgrade from Reduce to Hold indicates a more positive outlook on Moderna's stock by HSBC. However, the lowering of the price target from $89 to $69 suggests that HSBC believes the stock is currently overvalued. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100